N&O Index Card

Subject/Name: Glaxo, Inc.

Article(s) Referenced In:

1. Glaxo exec takes on new title; Mario seen as likely heir to chairmanship - Ja 1 92, 6C
2. Sanders now chairman and CEO of Glaxo, Inc. - Ja 7 92, 1D
3. Glaxo makes choice for marketing post; Executive (Morrow) to oversee new drugs' promotion - Ja 14 92, 1D
4. Glaxo cuts cost to clinics; Move seen as effort to avoid mandates - Fe 5 92, 9C
5. New drugs boost profits for Glaxo parent - Fe 21 92, 7C
6. Glaxo chooses new VP for research, development (Niedel) - Mr 4 92, 9C
7. Glaxo drug likely to cause fiscal pains as it cures migraines - Mr 29 92, 1F
8. Glaxo contributes to Durham Service Corps - Ap 1 92, 9C
9. How Zantac dethroned Tagamet; Glaxo parlayed slight edge over rival ulcer treatment into No. 1 - drug - Ap 12 92, 4F
10. Stark portrait paints Merck in white, Glaxo in black - Ap 12 92, 4F
11. Glaxo faces $1 billion decision; Dividend, acquisition among several options - Ap 19 92, 1F
12. Glaxo Holdings, biotech firm form partnership - Ap 21 92, 1D
13. Glaxo donates TB treatment - Ap 30 92, 10C
14. Glaxo calendar upsets pharmacist; Firm apologizes for entry on generic drugs - My 8 92, 6C
15. Glaxo gives prize ulcer pill a new, unique look - My 9 92, 12C
16. Glaxo offers Durham a bargain for prime ballpark site - My 29 92, 2B
17. Glaxo to market Zantac to treat new ailment - Jn 4 92, 7C
18. Glaxo Holdings, Ivax to make new type of inhaler device - Jn 17 92, 9C
19. Glaxo woods doctors from tent at boat races - Jy 19 92, 1F
20. Glaxo drug (Zofran) gets big boost - Se 5 92, 8C
21. Glaxo, Calif. firm forge research ties - Se 10 92, 10C
22. 4 companies give boost to child care; Area firms to spend $189,000 - Se 11 92, 6C
23. Glaxo receives award from Labor Department - Se 18 92, 6C
24. Firms offer child care - Se 21 92, 1B
25. FDA approval of Glaxo drug moving slowly - Oc 9 92, 6C
26. New Glaxo product to be a first; Skin test kit will be non-prescription item - Oc 28 92, 9C
27. Glaxo offers stock options to lower ranks - De 10 92, 7C
28. Glaxo chief perceives Clinton support for innovation - De 16 92, 9C
29. Glaxo executive (Ingram) will handle sales, marketing in No. 2 spot - De 22 92, 1D
30. FDA approves Glaxo's migraine drug (Imitrex) - De 30 92, 1

See a typo in our data? Let us know and we'll fix it.